SPAIN | ACTIS
06/11/2019
Lmite 19 Ene 2022
Oferta Tecnolgica
Ref.
TOUK20201216001
Anti-CD3 used in immuno-suppressive drugs for the treatment of leukaemia, offered to oncology researchers via licencing agreement
A UK non-profit organisation is providing access to Anti-CD3 (Anti-Cluster of Differentiation) from its original source Cancer Research UK, to academia and life science industry. The Anti-CD3 antibody is used as a pan T-cell marker in the detection of T-cell populations and in immuno-suppressive drugs for the treatment of leukaemia and is offered to cancer researchers and scientists in academia and industry, via licensing agreement.
Socios

logotipo CEOE Aragnlogotipo ITAINNOVAlogotipo Cmara Toledologotipo FEDAlogotipo UCLM
logotipo FUNDECYT-PCTEX logotipo ADERlogotipo FERlogotipo AINlogotipo UNAV

06/11/2019

Requerimientos: IE 6.0+, FF 1.5+ 1024x768+ | Aviso Legal | Confidencialidad

06/11/2019